Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

In a May 8 letter to HHS Secretary Robert F. Kennedy Jr. provided exclusively to KFF Health News, Wyden, the top Democrat on ...

FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...

(Gray News) - A combination shot for flu and COVID-19 using messenger RNA-generated antibodies in a study, but U.S. government regulators want to see data on whether the new vaccine protects people ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.